Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIxico Regulatory News (IXI)

Share Price Information for Ixico (IXI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 7.00
Bid: 6.75
Ask: 7.25
Change: 0.00 (0.00%)
Spread: 0.50 (7.407%)
Open: 7.00
High: 7.00
Low: 7.00
Prev. Close: 7.00
IXI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

11 May 2006 10:35

Phytopharm PLC11 May 2006 NOTIFICATION OF TRANSACTIONS OF DIRECTORS, PERSONS DISCHARGING MANAGERIAL RESPONSIBILITY OR CONNECTED PERSONS This form is intended for use by an issuer to make a RIS notification requiredby DR 3.1.4R(1). (1) An issuer making a notification in respect of a transaction relating to the shares or debentures of the issuer should complete boxes 1 to 16, 23 and 24. (2) An issuer making a notification in respect of a derivative relating to the shares of the issuer should complete boxes 1 to 4, 6, 8, 13, 14, 16, 23 and 24. (3) An issuer making a notification in respect of options granted to a director/person discharging managerial responsibilities should complete boxes 1 to 3 and 17 to 24. (4) An issuer making a notification in respect of a financial instrument relating to the shares of the issuer (other than a debenture) should complete boxes 1 to 4, 6, 8, 9, 11, 13, 14, 16, 23 and 24. Please complete all relevant boxes in block capital letters. 1. Name of the issuer PHYTOPHARM PLC 2. State whether the notification relates to (i) a transaction notified in accordance with DR 3.1.4R(1)(a); or (ii) DR 3.1.4(R)(1)(b) a disclosure made in accordance with section 324 (as extended by section 328) of the Companies Act 1985; or (iii) both (i) and (ii) NOTIFICATION RELATES TO (iii) 3. Name of person discharging managerial responsibilities/director DR RICHARD DIXEY 4. State whether notification relates to a person connected with a person discharging managerial responsibilities/director named in 3 and identify the connected person AS 3 ABOVE 5. Indicate whether the notification is in respect of a holding of the person referred to in 3 or 4 above or in respect of a non-beneficial interest 6. Description of shares (including class), debentures or derivatives or financial instruments relating to shares 7. Name of registered shareholders(s) and, if more than one, the number of shares held by each of them 8. State the nature of the transaction 9. Number of shares, debentures or financial instruments relating to shares acquired 10. Percentage of issued class acquired (treasury shares of that class should not be taken into account when calculating percentage) 11. Number of shares, debentures or financial instruments relating to shares disposed 12. Percentage of issued class disposed (treasury shares of that class should not be taken into account when calculating percentage) 13. Price per share or value of transaction 14. Date and place of transaction 15. Total holding following notification and total percentage holding following notification (any treasury shares should not be taken into account when calculating percentage) 16. Date issuer informed of transaction If a person discharging managerial responsibilities has been granted options by the issuer complete the following boxes 17. Date of grant 9 MAY 2006 18. Period during which or date on which it can be exercised 9 MAY 2009 TO 8 MAY 2016 19. Total amount paid (if any) for grant of the option NIL 20. Description of shares or debentures involved (class and number) 35,175 PHYTOPHARM PLC ORDINARY 1 PENCE SHARES 21. Exercise price (if fixed at time of grant) or indication that price is to be fixed at the time of exercise FIFTY SIX PENCE 22. Total number of shares or debentures over which options held following notification 473,614 23. Any additional information PERFORMANCE CRITERIA ARE BASED ON TOTAL SHAREHOLDER RETURN COMPARED TO COMPARATOR GROUPS ON THE THIRD ANNIVERSARY OF GRANT. NO OPTIONS VEST FOR BELOW MEDIAN PERFORMANCE AND 100% VEST FOR UPPER QUARTILE PERFORMANCE AND ABOVE WITH PRO RATA VESTING BETWEEN MEDIAN AND UPPER QUARTILE PERFORMANCE. FOR 23,450 OPTIONS THE COMPARATOR GROUP COMPRISES 25 OTHER UK LISTED BIOTECH COMPANIES AND FOR 11,725 OPTIONS THE COMPARATOR GROUP IS THE FTSE SMALL CAP INDEX 24. Name of contact and telephone number for queries ZOE MCGOWAN 01480 437697 Name and signature of duly authorised officer of issuer responsible for making notification Date of notification 11 MAY 2006 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
1st Mar 20217:00 amRNSConference attendance and presentations
29th Jan 202110:19 amRNSPDMR Dealing
21st Jan 202111:05 amRNSResult of AGM
7th Jan 20217:00 amRNSIssue of Equity
24th Dec 20207:00 amRNSIXICO secures new contract for £3.4 million
14th Dec 202011:54 amRNSHolding(s) in Company
8th Dec 20207:00 amRNSIXICO contract with new large global pharma
3rd Dec 20202:06 pmRNSSecond Price Monitoring Extn
3rd Dec 20202:01 pmRNSPrice Monitoring Extension
2nd Dec 20207:00 amRNSFinancial Results for the year ended 30 Sept 2020
27th Nov 20207:00 amRNSIXICO announces £1.9 million new study award
9th Nov 20207:00 amRNSNotice of Results
3rd Nov 20207:00 amRNSAdditional Alzheimer’s disease contracts
22nd Oct 20207:00 amRNSFurther Huntington’s disease contracts
19th Oct 20207:00 amRNSIXICO to Present at SCA & ARCA Global Conference
19th Oct 20207:00 amRNSTrading Update for year ended 30 September 2020
16th Oct 20207:00 amRNSIXICO and NYU Langone Health sign agreement
30th Sep 20202:05 pmRNSSecond Price Monitoring Extn
30th Sep 20202:00 pmRNSPrice Monitoring Extension
29th Sep 20207:00 amRNS>£2m contract extension win - Huntington’s disease
24th Sep 20207:00 amRNSCollaboration with TRACK-FA NeuroimagingConsortium
21st Sep 20207:00 amRNSIXICO selected to support Alzheimer’s trial
11th Sep 202010:36 amRNSHolding(s) in Company
26th Aug 202011:55 amRNSInvestor presentation
24th Aug 20209:05 amRNSSecond Price Monitoring Extn
24th Aug 20209:00 amRNSPrice Monitoring Extension
24th Aug 20207:00 amRNSTrading Update
13th Aug 20207:00 amRNSInvestor Presentation
8th Jul 20207:00 amRNSConference attendance - On Helix Digital
6th Jul 20207:00 amRNSGrant of share options
24th Jun 20207:00 amRNSTrading Update
20th May 20207:00 amRNSHalf yearly report to 31 March 2020
12th May 20207:00 amRNSNotice of Results
20th Apr 20207:00 amRNSTrading update for H1 2020
14th Apr 20207:00 amRNS£10.5m contract win, update on trading & COVID-19
16th Mar 20209:00 amRNSIXICO announces expanded contract with Vaccinex
2nd Mar 202011:05 amRNSSecond Price Monitoring Extn
2nd Mar 202011:00 amRNSPrice Monitoring Extension
26th Feb 202011:05 amRNSSecond Price Monitoring Extn
26th Feb 202011:00 amRNSPrice Monitoring Extension
19th Feb 20209:00 amRNSIXICO to Present AI Segmentation Research
17th Feb 20204:40 pmRNSSecond Price Monitoring Extn
17th Feb 20204:35 pmRNSPrice Monitoring Extension
17th Feb 20202:05 pmRNSSecond Price Monitoring Extn
17th Feb 20202:00 pmRNSPrice Monitoring Extension
11th Feb 20207:00 amRNSHolding(s) in Company
10th Feb 20209:11 amRNSIXICO to Present at Innovation Forum
3rd Feb 20209:00 amRNSIXICO Supports the AD Neuroimaging Initiative
23rd Jan 20207:00 amRNSDirector/PDMR Shareholding
17th Jan 20204:34 pmRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.